TABLE 1

Clinical Characteristics Associated With Sildenafil Use

VariableBPD-PH Cohorta (n = 598)Received Sildenafilb (n = 104 [17%])Multivariate Logistic ORc (95% CI)
Gestation, wk
 27–28181 (30.3)18 (17.3)
 25–26226 (37.8)44 (42.3)2.26* (1.20–4.24)
 ≤24191 (31.9)42 (40.4)3.21*** (1.66–6.21)
BPD severity
 Mild84 (14.1)4 (3.9)
 Moderate346 (57.9)53 (51.1)3.03* (1.03–8.93)
 Severe168 (28.1)47 (45.2)7.56*** (2.50–22.88)
SGA status
 No530 (88.6)85 (81.7)
 Yes68 (11.4)19 (18.3)2.32* (1.21–4.46)
Comorbidities
 NEC96 (16.1)15 (14.4)0.66 (0.34–1.29)
 PDA446 (74.6)79 (75.9)1.15 (0.66–1.99)
 IVHd127 (21.2)15 (14.4)0.55 (0.29–1.03)
 ROP330 (55.2)54 (51.9)0.68 (0.42–1.10)
  • * P < .05, ***P < .001. —, relative to the reference group.

  • a Frequency and percentage (in parentheses) of patients with the study characteristic.

  • b Frequency and percentage of patients with BPD-PH who received sildenafil.

  • c OR (95% CI) from multivariate logistic regression with OR relative to the reference group indicated by (–).

  • d Severe IVH defined as grade 3 or 4 hemorrhage on head ultrasound.